Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
vaccine_innovation_prioritisation_strategy [2022/08/07 00:43] liam [Microarray patches] | vaccine_innovation_prioritisation_strategy [2024/01/02 07:32] (current) liam |
---|
| |
The **Vaccine Innovation Prioritisation Strategy (VIPS) Alliance** is a supranational collaborative initiative. It consists of the [[Bill & Melinda Gates Foundation]], [[Gavi|Gavi, the Vaccine Alliance]], [[PATH]], [[UNICEF]] and the [[World Health Organization]].((//The Vaccine Innovation Prioritisation Strategy.// (2021, June 30). Gavi, the Vaccine Alliance. https://archive.ph/eZMoO)) | The **Vaccine Innovation Prioritisation Strategy (VIPS) Alliance** is a supranational collaborative initiative. It consists of the [[Bill & Melinda Gates Foundation]], [[Gavi|Gavi, the Vaccine Alliance]], [[PATH]], [[UNICEF]] and the [[World Health Organization]].((//The Vaccine Innovation Prioritisation Strategy.// (2021, June 30). Gavi, the Vaccine Alliance. https://archive.ph/eZMoO)) |
| |
===== Activities ===== | ===== Activities ===== |
| |
==== Microarray patches ==== | ==== Microarray patches ==== |
| |
In May 2020, the VIPS Steering Committee selected and recommended three vaccine-related innovations to prioritize in order to increase uptake of [[vaccines]]. [[Microaray patches]] (MAPS) were identified as the highest priority (the other two were "heat-stable and controlled temperature chain qualified vaccines", and barcodes on primary packaging).((Vaccine Innovation Prioritisation Strategy (VIPS). (2021). //Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan// (p. 2). Gavi, the Vaccine Alliance. https://web.archive.org/web/20220806221838/https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf)) During the second half of 2020 and into 2021, the VIPS Working Group published a five-year plan to develop these MAPS. | In May 2020, the VIPS Steering Committee selected and recommended three vaccine-related innovations to prioritize in order to increase uptake of [[vaccines]]. [[Microarray patches]] (MAPS) were identified as the highest priority (the other two were "heat-stable and controlled temperature chain qualified vaccines", and barcodes on primary packaging).((Vaccine Innovation Prioritisation Strategy (VIPS). (2021). //Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan// (p. 2). Gavi, the Vaccine Alliance. https://web.archive.org/web/20220806221838/https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf)) During the second half of 2020 and into 2021, the VIPS Working Group published a five-year plan to develop these MAPS. |
| |
MAPS are small devices that "consist of an array of hundreds to thousands of micro-projections on a patch or backing. These micro-projections can be coated with, or are composed of, vaccine in a dry formulation." After being applied to the skin, the vaccine payload is delivered into the dermis and/or epidermis of the skin, which are rich in [[antigen]]-presenting cells. The two main types of MAPS being developed are solid-coated and dissolving. | MAPS are small devices that "consist of an array of hundreds to thousands of micro-projections on a patch or backing. These micro-projections can be coated with, or are composed of, vaccine in a dry formulation." After being applied to the skin, the vaccine payload is delivered into the dermis and/or epidermis of the skin, which are rich in [[antigen]]-presenting cells. The two main types of MAPS being developed are solid-coated and dissolving. |
| |
A number of organizations are funding the development MAPS including the [[Bill & Melinda Gates Foundation]], [[Biomedical Advanced Research and Development Authority]] (BARDA), the U.S. [[Centers for Disease Control and Prevention]] (CDC), and the [[World Health Organization]] (WHO). Developing companies include [[pharmaceutical_companies:Micron Biomedical]], the [[University of Connecticut]], [[pharmaceutical_companies:Vaxess]], [[pharmaceutical_companies:Vaxxas]] and [[pharmaceutical_companies:Verndari]]. | A number of organizations are funding the development of MAPS including the [[Bill & Melinda Gates Foundation]], [[Biomedical Advanced Research and Development Authority]] (BARDA), the U.S. [[Centers for Disease Control and Prevention]] (CDC), and the [[World Health Organization]] (WHO). Developing companies include [[pharmaceutical_companies:Micron Biomedical]], the [[University of Connecticut]], [[pharmaceutical_companies:Vaxess]], [[pharmaceutical_companies:Vaxxas]] and [[pharmaceutical_companies:Verndari]]. |
| |
VIPS estimates early pilot programs for MAPS will begin no earlier than 2026. | VIPS estimates early pilot programs for MAPS will begin no earlier than 2026. |
| |
| ===== Personnel ===== |
| |
| ^ VIPS Steering Committee((Vaccine Innovation Prioritisation Strategy. //VIPS Steering Committee members.// Gavi, the Vaccine Alliance. Retrieved August 6, 2022, from https://archive.ph/4ZbZG)) ^^^ |
| ^ Name ^ Affiliation ^ Role ^ |
| | [[Alejandro Cravioto]] | [[Universidad Nacional Autónoma de México]] | Professor; SAGE Chair | |
| | [[David Robinson]] | [[Bill & Melinda Gates Foundation]] | Deputy Director of Vaccine Development and Surveillance, Chemistry Manufacturing and Controls | |
| | [[Christopher Morgan]] | [[Jhpiego]] and [[Burnet Institute]] | Senior Technical Advisor (Immunization) and Honorary Senior Principal Research Fellow | |
| | [[David Kaslow]] | [[PATH]] | Vice president, Essential Medicines | |
| | [[Jean-Pierre Amorij]] | [[UNICEF]] Supply Division | Vaccine Technology Specialist | |
| | [[Jerome Kim]] | [[International Vaccine Institute]] | Director General | |
| | [[Jon Abramson]] | [[Wake Forest School of Medicine]] | Professor of Pediatric Infectious Diseases | |
| | [[Kelly Moore]] | [[Vanderbilt University School of Medicine]] | Adjunct Associate Professor of Health Policy | |
| | [[Mark Jit]] | [[London School of Hygiene and Tropical Medicine]] | Professor, Vaccine Epidemiology | |
| | [[Mark Papania]] | [[Centers for Disease Control and Prevention]] (CDC) Global Immunization Division | Medical Epidemiologist | |
| | [[Michael Free]] | Independent | Independent Consultant; Senior Advisor Emeritus, [[PATH]] | |
| | [[Nora Dellepiane]] | [[QRB Consultants Sàrl]] | Independent consultant | |
| | [[Ramanan Laxminarayan]] | [[Center for Disease Dynamics, Economics and Policy]] | Director | |
| | [[Ruth Karron]] | [[Johns Hopkins University]] | Professor, International Health | |
| | [[Samir Sodha]] | [[World Health Organization]] | Routine Immunization Officer | |
| | [[Shelley Deeks]] | [[Public Health Ontario]] | Chief Health Protection Officer | |